The Performance of Multi-tracer Multimodality PET in Lymphoma

Recruiting

• Conditions: Positron-Emission Tomography

• Registration Number: NCT05004961
• Lead Sponsor: Peking University Cancer Hospital & Institute

Brief Summary

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

Detailed Description

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Study Timeline

• Study Start: 2019-09-15
• Study First Submitted: 2021-08-07
• Study First Submitted QC: 2021-08-07
• Study First Posted: 2021-08-13
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-02
• Last Update Posted: 2023-03-03
• Primary Completion: 2023-08-15
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• pathologically diagnosed as lymphoma;
• Written informed consent for receiving FAPI-04 PET examinations.
• cancer planned chemotherapy or immunotherapy scheme.
• expected survival ≥ 12 weeks

Exclusion Criteria

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• severe liver or kidney dysfunction
• pregnancy or lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SUVmax	150 days	Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)

Trial Locations

Locations (1)

Peking University Cancer Hospital; 🇨🇳 Beijing, Beijing, China